一项临床试验显示，实验药物 ADI-PEG20 与化疗联合使用可使间皮瘤生存期延长 1.6 个月，三年生存率提高四倍。 Experimental drug ADI-PEG20 increased mesothelioma survival by 1.6 months and quadrupled three-year survival rate when combined with chemo, according to a clinical trial.

一种实验药物 ADI-PEG20 在治疗恶性间皮瘤（一种与石棉接触有关的罕见癌症）方面显示出良好的效果。 An experimental drug, ADI-PEG20, has shown promising results in treating malignant mesothelioma, a rare cancer linked to asbestos exposure. 在一项涉及 249 名患者的临床试验中，该药物与传统化疗联合使用，使间皮瘤患者的平均生存期延长了 1.6 个月，三年生存率提高了四倍。 In a clinical trial involving 249 patients, the drug increased average survival of mesothelioma patients by 1.6 months and quadrupled the three-year survival rate when combined with traditional chemotherapy. 该药物的有效性归因于癌细胞的精氨酸饥饿。 The drug's effectiveness has been attributed to the arginine starvation of cancer cells.